|
|
|
| Effects of Telmisartan Bisoprolol Combined with Trimetazidine on Plasma BNP and Fg Levels and Cardiopulmonary Function in Patients with COPD Complicated with CHD |
| DAI Kefen, YU Qian, WANG Wenjing, et al |
| Chengdu Third People's Hospital,Sichuan Chengdu 610000,China |
|
|
|
|
Abstract Objective: To explore the effects of telmisartan,bisoprolol combined with trimetazidine on plasma B-type natriuretic peptide (BNP) and fibrinogen (Fg) levels and cardiopulmonary function in patients with chronic obstructive pulmonary disease (COPD) complicated with coronary heart disease (CHD).Methods: 164 patients with COPD and CHD admitted to our hospital from March 2014 to March 2019 were selected,numbered according to the order of admission and randomly divided into study group and control group by sealed envelope method.82 cases in study group were given telmisartan + bisoprolol,and 82 cases in control group were treated with telmisartan,bisoprolol+trimetazidine.The changes of lung function indexes,cardiac function indexes,plasma BNP and Fg levels and serum inflammatory related indexes were compared between the two groups.Results: After treatment,the PEF,FVC and FEV1/FVC were significantly increased in the two groups (P<0.05),and the increases in study group were higher than those in control group (P<0.05).The LVEF in the two groups was significantly increased (P<0.05) while the LVEDD and LVESD were significantly decreased (P<0.05),and the changes in study group were greater than those in control group (P<0.05).The plasma BNP and Fg levels were significantly decreased in the two groups (P<0.05),and the decreases in study group were greater compared with those in control group.The serum levels of NF-κB,Chemerin,TGF-β and MMP-9 were significantly decreased in the two groups (P<0.05),and the decreases in study group were greater than those in control group (P<0.05).Conclusion: Telmisartan,bisoprolol combined with trimetazidine has exact efficacy in the treatment of COPD with CHD,and can significantly improve cardiopulmonary function,reduce plasma BNP and Fg levels,and inhibit synthetic release of serum NF-κB,Chemerin,TGF-β and MMP-9,and reduce the body’ s inflammatory damage.
|
|
|
|
|
|
[1] 殷晓明,朱红娟,王丹.老年慢性阻塞性肺疾病稳定期合并冠心病患者营养风险观察与分析[J].安徽医药,2018,22(9):1780~1782.
[2] 何玉,秦明照.慢性阻塞性肺疾病对冠状动脉粥样硬化性心脏病患者的影响[J].中国心血管杂志,2019,24(4):324~327.
[3] 吴利杰,马力.曲美他嗪治疗冠心病的疗效及对血管内皮功能运动耐量的影响[J].山西医药杂志,2019,48(24):3076~3078.
[4] 张家豪,孙超峰.伊伐布雷定治疗冠心病合并慢性阻塞性肺病心力衰竭临床疗效研究[J].陕西医学杂志,2019,48(2):256~258,273.
[5] 官海莲,陈妮.阿魏酸哌嗪片对伴心血管危险因素老年COPD患者血管内皮功能、颈动脉斑块性质及心肺功能的影响[J].中南医学科学杂志,2020,48(1):14~17.
[6] Ehilawa PI,Chisanga B,Smith P,et al.P195 Domiciliary noninvasive ventilation reduces re-admissions in persistent hypercapnic respiratory failure due to COPD,but are we missing a trick[J].Thorax,2019,74(2):195~204.
[7] 吴劲松,张艳,张怀中.比索洛尔联合曲美他嗪对射血分数保留心力衰竭老年病人的影响[J].实用老年医学,2018,32(11):45~48.
[8] 孔令银,马运华,曹雪茹.血小板参数在慢性阻塞性肺病合并肺心病患者中的变化及意义[J].检验医学与临床,2018,15(6):859~861.
[9] 王彦宏,郝东侠.盐酸曲美他嗪对老年急性心肌病患者的疗效及对血清细胞因子、心功能的影响[J].心血管康复医学杂志,2019,28(3):356~359.
[10] 刘廷怡,刘瑶,王安伟.美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床疗效[J].解放军预防医学杂志,2018,36(6):713~716.
[11] 张喆,李娜,刘谦,等.阿胶对COPD模型小鼠的保护作用以及对MMP-2、MMP-9、TGF-β1水平的影响[J].基因组学与应用生物学,2018,37(4):1813~1819. |
|
|
|
2020, Vol. 26 
